Hi-Tech Deal Broadens Akorn Consumer Business
This article was originally published in The Tan Sheet
Executive Summary
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
You may also be interested in...
In Brief: CHPA Disagrees With FDA Warning; Adulterated Supplements Enforcement; DASCA Support Sought
FDA warns about painkillers for teething; enforcement against adulterated supplements; FDA warning letter for tainted bee pollen; Akorn must divest brands from Hi-Tech deal; senators seek support for DASCA; and consumer acetaminophen knowledge improves.
In Brief: CHPA Disagrees With FDA Warning; Adulterated Supplements Enforcement; DASCA Support Sought
FDA warns about painkillers for teething; enforcement against adulterated supplements; FDA warning letter for tainted bee pollen; Akorn must divest brands from Hi-Tech deal; senators seek support for DASCA; and consumer acetaminophen knowledge improves.
In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.